Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways
Open accessAbstract
Single base pair mutations that alter the function of tumor suppressor genes and oncogenes occur frequently during oncogenesis. The guardian of the genome, p53, is inactivated by point mutation in more than 50% of human cancers. Synthetic small inhibiting RNAs (siRNAs) can suppress gene expression in mammalian cells, although their degree of selectivity might be compromised by an amplification mechanism. Here, we demonstrate that a single base difference in siRNAs discriminates between mutant and WT p53 in cells expressing both forms, resulting in the restoration of WT protein function. Therefore, siRNAs may be used to suppress expression of point-mutated genes and provide the basis for selective and personalized antitumor therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 2002, a single base difference was found between wild-type p53 and mutant p53, demonstrating that synthetic siRNAs are efficient tools to inactivate oncogenic mutations and restore p53 pathways.
“In 2002, a single base difference was found between wtp53 and mutp53, demonstrating that synthetic siRNAs are efficient tools to inactive oncogenic mutations and restore p53 pathways.573”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [573]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456 · see citing works
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,896 · see citing works
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295 · see citing works
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works
RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,308 · see citing works
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & Tuschl, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,449 · see citing works
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369 · see citing works
On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing
Sijen, T., Fleenor, J., Simmer, F., Thijssen, K. L., Parrish, S., Timmons, L., Plasterk, R. H. A., & Fire, A. Z. (2001) · Cell · doi:10.1016/s0092-8674(01)00576-1 · Cited by 1,280 · see citing works
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
Waldman, T. A., Kinzler, K. W., & Vogelstein, B. (1995) · PubMed · Cited by 1,203 · see citing works
Caplen, N. J., Parrish, S., Imani, F., Fire, A. Z., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,042 · see citing works
Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression
Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940 · see citing works
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works
Identification of essential genes in cultured mammalian cells using small interfering RNAs
Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T., & Weber, K. K. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.24.4557 · Cited by 828 · see citing works
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J. W., Lee, S., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 775 · see citing works
Aas, T., Børresen‐Dale, A., Geisler, S. B., Smith‐Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736 · see citing works
RNA interference—2001Preprint
Sharp, P. A. (2001) · Genes & Development · doi:10.1101/gad.880001 · Cited by 703 · see citing works
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669 · see citing works
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature reviews. Cancer · doi:10.1038/35094077 · Cited by 565 · see citing works
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511 · see citing works
The Human Papillomavirus E6 protein and its contribution to malignant progression
Mantovani, F., & Banks, L. (2001) · Oncogene · doi:10.1038/sj.onc.1204869 · Cited by 511 · see citing works
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417 · see citing works
RNAi as Random Degradative PCR
Lipardi, C., Qin, W., & Paterson, B. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00537-2 · Cited by 369 · see citing works
Transcriptional gene silencing in plants: targets, inducers and regulators
Vaucheret, H., & Fagard, M. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(00)02166-1 · Cited by 368 · see citing works
Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression
Kern, S. E., Pietenpol, J. A., Thiagalingam, S., et al. (1992) · Science · doi:10.1126/science.256.5058.827 · Cited by 342 · see citing works
Activation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337 · see citing works
Multiple roles of the tumor suppressor p53
Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332 · see citing works
Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C., & Tainsky, M. A. (1990) · PubMed · Cited by 252 · see citing works
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241 · see citing works
Harvey, M., Vogel, H. S., Morris, D. K., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 228 · see citing works
Nishikura, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00581-5 · Cited by 174 · see citing works
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 161 · see citing works
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127 · see citing works
Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA
Kisielow, M., Kleiner, S., Nagasawa, M., Faisal, A., & Nagamine, Y. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3630001 · Cited by 96 · see citing works
Kitami, T., & Nadeau, J. H. (2002) · Nature Genetics · doi:10.1038/ng1202-681a · Cited by 79 · see citing works
Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA
Kisielow, M., Kleiner, S., Nagasawa, M., et al. (2002) · Biochemical Journal · doi:10.1042/bj3630001 · Cited by 65 · see citing works
Birch, J. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00383-g · Cited by 57 · see citing works
Cyclin E Restores p53 Activity in Contact-Inhibited Cells
Deffie, A. M., Hao, M., Luna, R. M. D. O., Hulboy, D. L., & Lozano, G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3926 · Cited by 28 · see citing works
Self-citationJõers, A., Kristjuhan, A., Kadaja, L., & Maimets, T. (1998) · Oncogene · doi:10.1038/sj.onc.1202146 · Cited by 21 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Caplen, N. J., Parrish, S., Imani, F., Fire, A. & Morgan, R. A. (2001) Proc. Natl. Acad. Sci. USA 98, 9742-9747.
Cited by
Sorted by citations
MicroRNA targets in Drosophila
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597 · see citing works
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · see citing works
Small silencing RNAs: an expanding universe
Ghildiyal, M., & Zamore, P. D. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2504 · Cited by 2,314 · see citing works
A biochemical framework for RNA silencing in plantsPreprint
Tang, G., Reinhart, B. J., Bartel, D. P., & Zamore, P. D. (2003) · Genes & Development · doi:10.1101/gad.1048103 · Cited by 984 · see citing works
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 773 · see citing works
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677 · see citing works
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N. N., & Nemunaitis, J. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 658 · see citing works
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works
Wilderman, P. J., Sowa, N. A., FitzGerald, D. J., FitzGerald, P. C., Gottesman, S., Ochsner, U. A., & Vasil, M. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403423101 · Cited by 455 · see citing works
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Harborth, J., Elbashir, S. M., Vandenburgh, K., Manninga, H., Scaringe, S. A., Weber, K., & Tuschl, T. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003321629638 · Cited by 474 · see citing works
RNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382 · see citing works
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 335 · see citing works
The canonical Wnt signalling pathway and its APC partner in colon cancer development
Schneikert, J., & Behrens, J. (2006) · Gut · doi:10.1136/gut.2006.093310 · Cited by 289 · see citing works
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L. A., Moore, J. T., Schelter, J. M., Burchard, J., Linsley, P. S., D, N. A. M., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 271 · see citing works
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 259 · see citing works
Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253 · see citing works
Self-citationTherapeutic potential of RNA interference against cancer
Takeshita, F., & Ochiya, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00234.x · Cited by 239 · see citing works
Towards applications of bioentities@MOFs in biomedicine
Velásquez-Hernández, M. D. J., Linares‐Moreau, M., Astria, E., Carraro, F., Alyami, M., Khashab, N. M., Sumby, C. J., Doonan, C. J., & Falcaro, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213651 · Cited by 238 · see citing works
Chen, P., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2007) · RNA · doi:10.1261/rna.789808 · Cited by 206 · see citing works
Dayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 200 · see citing works
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
Nieth, C., Priebsch, A., Stege, A., & Lage, H. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00523-4 · Cited by 200 · see citing works
Leal, C., Bouxsein, N. F., Ewert, K. K., & Safinya, C. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1059763 · Cited by 195 · see citing works
Lipid nanoparticle delivery systems for siRNA-based therapeutics
Wan, C. P. L., Allen, T. M., & Cullis, P. R. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 194 · see citing works
Miller, V. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh208 · Cited by 170 · see citing works
The therapeutic potential of RNA interference
Uprichard, S. L. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.004 · Cited by 161 · see citing works
Ewert, K. K., Zidovska, A., Ahmad, A. K., Bouxsein, N. F., Evans, H. M., McAllister, C. S., Samuel, C. E., & Safinya, C. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_70 · Cited by 155 · see citing works
Bouxsein, N. F., McAllister, C. S., Ewert, K. K., Samuel, C. E., & Safinya, C. R. (2007) · Biochemistry · doi:10.1021/bi062138l · Cited by 155 · see citing works
Many commonly used siRNAs risk off-target activity
Snøve, O., & Holen, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.175 · Cited by 149 · see citing works
Lombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Maria, E. D., Donato, S. D., & Kaemmerer, W. F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.004 · Cited by 124 · see citing works
Metabolic vulnerability of cisplatin‐resistant cancers
Obrist, F., Michels, J., Durand, S., Chery, A., Pol, J. G., Lévesque, S., Joseph, A., Astesana, V., Pietrocola, F., Wu, G. S., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798597 · Cited by 122 · see citing works
Petrick, J. S., Brower‐Toland, B. D., Jackson, A. L., & Kier, L. D. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.03.008 · Cited by 126 · see citing works
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117 · see citing works
van Bilsen, P. H. J., Jaspers, L., Lombardi, M. S., Odekerken, J. C. E., Burright, E. N., & Kaemmerer, W. F. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.116 · Cited by 114 · see citing works
Sioud, M. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.11.006 · Cited by 111 · see citing works
The aggregation of mutant p53 produces prion-like properties in cancer
Rangel, L. P., da Costa, D. C. F., Vieira, T. C. R. G., & Silva, J. L. (2014) · Prion · doi:10.4161/pri.27776 · Cited by 109 · see citing works
RNA Interference: A Potent Tool for Gene-Specific Therapeutics
Ichim, T. E., Li, M., Qian, H., Popov, I. A., Rycerz, K., Zheng, X., White, D. J., Zhong, R., & Min, W. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00530.x · Cited by 107 · see citing works
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 102 · see citing works
Inhalable siRNA: Potential as a Therapeutic Agent in the Lungs
Durcan, N., Murphy, C., & Cryan, S. (2008) · Molecular Pharmaceutics · doi:10.1021/mp070048k · Cited by 101 · see citing works
Strategies for targeting undruggable targets
Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 102 · see citing works
Preeclampsia Is Associated with Alterations in the p53-Pathway in Villous Trophoblast
Sharp, A. N., Heazell, A. E. P., Baczyk, D., Dunk, C., Lacey, H. A., Jones, C. J. P., Perkins, J., Kingdom, J. C., Baker, P. N., & Crocker, I. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087621 · Cited by 98 · see citing works
PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Saha, M. N., Jiang, H., Yang, Y., Reece, D. E., & Chang, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1166 · Cited by 99 · see citing works
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 91 · see citing works
E2F3 Is a Mediator of DNA Damage-Induced Apoptosis
Martinez, L. A., Goluszko, E., Chen, H., Leone, G. W., Post, S. M., Lozano, G., Chen, Z., & Chauchereau, A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00938-09 · Cited by 87 · see citing works
Self-citationPharmaceutical Prospects for RNA Interference
Schiffelers, R. M., Woodle, M. C., & Scaria, P. V. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000012145.49054.6c · Cited by 86 · see citing works
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84 · see citing works
Kiang, A., Palfi, A., Ader, M., Kenna, P. F., Millington‐Ward, S., Clark, G., Kennan, A., O’Reilly, M., Tam, L. C. S., Aherne, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.028 · Cited by 83 · see citing works
An Efficient System for Cap- and Poly(A)-Dependent Translation In Vitro
Svitkin, Y. V., & Sonenberg, N. (2004) · Humana Press eBooks · doi:10.1385/1-59259-750-5:155 · Cited by 80 · see citing works
Denti, M. A., Rosa, A., Sthandier, O., Angelis, F. G. D., & Bozzoni, I. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.008 · Cited by 76 · see citing works
RNA interference: on the road to an alternate therapeutic strategy!
Dave, R. S., & Pomerantz, R. J. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.407 · Cited by 73 · see citing works
microRNAs and cancer: role in tumorigenesis, patient classification and therapy
Hernando, E. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0029-0 · Cited by 71 · see citing works
Ichwan, S. J. A., Yamada, S., Sumrejkanchanakij, P., Auerkari, E. I., Eto, K., & Ikeda, M.-A. (2005) · Oncogene · doi:10.1038/sj.onc.1209158 · Cited by 68 · see citing works
p53 Regulation and Function in Renal Cell Carcinoma
Warburton, H. E., Brady, M., Vlatković, N., Linehan, W. M., PARSONS, K. F., & Boyd, M. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0017 · Cited by 63 · see citing works
Silence of the transcripts: RNA interference in medicine
Barik, S. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0690-0 · Cited by 61 · see citing works
Leal, C., Ewert, K. K., Shirazi, R. S., Bouxsein, N. F., & Safinya, C. R. (2011) · Langmuir · doi:10.1021/la200679x · Cited by 60 · see citing works
Efficient and specific down-regulation of prion protein expression by RNAi
Tilly, G., Chapuis, J., Vilette, D., Laude, H., & Vilotte, J.-L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00805-2 · Cited by 60 · see citing works
Selective killing of p53‐deficient cancer cells by SP600125
Jèmaà, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Mariño, G., Malik, S. A., Rello‐Varona, S., Lissa, D., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200228 · Cited by 57 · see citing works
RNAi: ancient mechanism with a promising future
Geley, S., & Muller, C. R. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.03.040 · Cited by 58 · see citing works
Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling
Ashley, N., & Poulton, J. (2009) · Oncogene · doi:10.1038/onc.2009.242 · Cited by 57 · see citing works
Jiang, F., Caraway, N. P., Li, R., & Katz, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208459 · Cited by 57 · see citing works
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy
Chen, Y., & Huang, L. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802568505 · Cited by 55 · see citing works
Design of active small interfering RNAs.
Peek, A. S., & Behlke, M. A. (2007) · PubMed · Cited by 51 · see citing works
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50 · see citing works
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents
Youlyouz‐Marfak, I., Gachard, N., Clorennec, C. L., Najjar, I., Baran‐Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., & Feuillard, J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402270 · Cited by 50 · see citing works
The changing face of p53 in head and neck cancer
Partridge, M., Costea, D. E., & Huang, X. (2007) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2007.06.006 · Cited by 50 · see citing works
Jiang, W.-Q., Zhong, Z.-H., Nguyen, A., Henson, J. D., Toouli, C., Braithwaite, A., & Reddel, R. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200810084 · Cited by 58 · see citing works
High-throughput gene silencing using cell arrays
Vanhecke, D., & Janitz, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208027 · Cited by 48 · see citing works
Functional genomics using high-throughput RNA interference
Vanhecke, D., & Janitz, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03352-5 · Cited by 47 · see citing works
Zheng, J., Teng-xiang, M., Cao, J., Sun, X., Chen, J., Li, W., Wen, R.-M., Sun, Y., & Pei, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.064 · Cited by 46 · see citing works
The ABCC4 gene is a promising target for pancreatic cancer therapy
Zhang, Z., Wang, J., Shen, B., Peng, C., & Zheng, M. (2011) · Gene · doi:10.1016/j.gene.2011.09.029 · Cited by 46 · see citing works
Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells
Beurel, E., Eggelpoël, M.-J. B.-V., Kornprobst, M., Moritz, S., Delelo, R., Paye, F., Housset, C., & Desbois‐Mouthon, C. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.026 · Cited by 46 · see citing works
Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research
Dasgupta, R., & Perrimon, N. (2004) · Oncogene · doi:10.1038/sj.onc.1208028 · Cited by 46 · see citing works
Molecular genetics of head and neck squamous cell carcinoma
Saâda-Bouzid, E., Peyrade, F., & Guigay, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000536 · Cited by 45 · see citing works
The role of p73 in hematological malignancies
Pluta, A., Nyman, U., Joseph, B., Robak, T., Zhivotovsky, B., & Smolewski, P. (2006) · Leukemia · doi:10.1038/sj.leu.2404166 · Cited by 45 · see citing works
Duiker, E. W., Meijer, A., van der Bilt, A. R. M., Meersma, G. J., Kooi, N. M., van der Zee, A. G. J., de Vries, E. G. E., & de Jong, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.84 · Cited by 44 · see citing works
Selective silencing of a mutant transthyretin allele by small interfering RNAs
Kurosawa, T., Igarashi, S., Nishizawa, M., & Onodera, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.142 · Cited by 43 · see citing works
Single domain antibodies for the knockdown of cytosolic and nuclear proteins
Böldicke, T. W. (2017) · Protein Science · doi:10.1002/pro.3154 · Cited by 43 · see citing works
Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors
Zhang, H., Wang, H., Zhang, J., Qian, G., Niu, B., Fan, X., Lu, J., Hoffman, A. R., Hu, J., & Ge, S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.236 · Cited by 42 · see citing works
Koivusalo, R., Mialon, A., Pitkänen, H., Westermarck, J. K., & Hietanen, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2185 · Cited by 42 · see citing works
RNA silencing in viral infections: insights from poliovirus
Saleh, M., van Rij, R. P., & Andino, R. (2004) · Virus Research · doi:10.1016/j.virusres.2004.01.010 · Cited by 41 · see citing works
Coordination-based self-assembled capsules (SACs) for protein, CRISPR–Cas9, DNA and RNA delivery
Alimi, L. O., Alyami, M., Chand, S., Baslyman, W. S., & Khashab, N. M. (2021) · Chemical Science · doi:10.1039/d0sc05975g · Cited by 39 · see citing works
Cui, W., Ning, J., Naik, U. P., & Duncan, M. K. (2003) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2003.09.002 · Cited by 38 · see citing works
Inhibition of galectins in cancer: Biological challenges for their clinical application
Laderach, D. J., & Compagno, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1104625 · Cited by 38 · see citing works
Potential applications of RNA interference technology in the treatment of cancer.
Lage, H. (2005) · Future Oncology · doi:10.1517/14796694.1.1.103 · Cited by 39 · see citing works
Sharma, S. K., & Münger, K. (2020) · mBio · doi:10.1128/mbio.01190-20 · Cited by 34 · see citing works
Development of gene-specific double-stranded RNA drugs
Barik, S. (2004) · Annals of Medicine · doi:10.1080/07853890410018817 · Cited by 34 · see citing works
Coupling of RNAi-Mediated Target Downregulation with Gene Replacement
Kim, D., & Rossi, J. J. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003768247619 · Cited by 33 · see citing works
RNA Interference—A Silent but an Efficient Therapeutic Tool
Ramachandran, P. V., & Savarimuthu Ignacimuthu, S. J. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0098-1 · Cited by 32 · see citing works
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2015) · Oncotarget · doi:10.18632/oncotarget.6634 · Cited by 30 · see citing works
Self-citationScherr, M., Battmer, K., Dallmann, I., Ganser, A., & Eder, M. (2003) · Oligonucleotides · doi:10.1089/154545703322617032 · Cited by 31 · see citing works
RNA molecules as anti-cancer agents
Friedrich, I., Shir, A., KLEIN, S., & Levitzki, A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.001 · Cited by 31 · see citing works
RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research
Chang, H. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701063 · Cited by 30 · see citing works
Gene Discovery in Cervical Cancer
Martin, C. M., Kehoe, L., Spillane, C. D., & O’Leary, J. J. (2007) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256249 · Cited by 29 · see citing works
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
Jedidi, A., Marty, C., Oligo, C., Jeanson, L., Ribeil, J., Casadevall, N., Galy, A. H. M., Vainchenker, W., & Villeval, J. (2009) · Blood · doi:10.1182/blood-2008-09-176875 · Cited by 28 · see citing works
p53 mutations and resistance to chemotherapy: A stab in the back for p73
Soussi, T. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00081-3 · Cited by 28 · see citing works
Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Trochet, D., Prudhon, B., Vassilopoulos, S., & Bitoun, M. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150812115730 · Cited by 27 · see citing works
p73: regulator in cancer and neural development
Irwin, M. S., & Miller, F. D. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401452 · Cited by 27 · see citing works
Gene‐specific mechanisms of p53 transcriptional control and prospects for cancer therapy
Resnick‐Silverman, L., & Manfredi, J. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20925 · Cited by 27 · see citing works
- Authors
- Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Scripps Research Institute (US)
- Unité Propre de Recherche 9079, Centre National de la Recherche Scientifique-Ligue Nationale Contre le Cancer, Service de Cytofluorométrie, Unité Propre de Recherche 1983, Centre National de la Recherche Scientifique, Institut André Lwoff, 7 Rue Guy Moquet, 94800 Villejuif, France; and University of Texas M. D. Anderson Cancer Center, Department of Molecular Genetics, Section of Cancer Genetics, 1515 Holcombe Boulevard, Houston, TX 77030
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-10-28
- Volume
- 99
- Issue
- 23
- Pages
- 14849-14854
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC137507
- OpenAlex
- W2017991840
- Cited by
- 210
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 4 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Philippe Foundation
- National Cancer Institute (CA09212502)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- siRNA, p53, point mutations, tumor suppressor, oncogenes, cancer therapy, precision oncology, gene expression inhibition
- MeSH terms
- Base Sequence, Humans, Mutation, Gene Expression Regulation, Neoplastic, Genes, p53, Tumor Suppressor Protein p53, Point Mutation, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
